- Mankind Pharma Limited (NSE: MANKIND, BSE: 543904) approved an additional investment of up to EUR 45 million in its Dutch subsidiary, raising the total authorized capital to EUR 50 million.
- The board also approved the purchase of 70 % of Armed Cell Therapeutics B.V. (ACTx) for EUR 48 million in cash, to be paid in instalments.
- The EUR 45 million infusion into the Dutch subsidiary is a related‑party transaction exempt under SEBI regulations; the EUR 48 million cash payment for ACTx is not a related‑party deal.
- Acquiring ACTx gives MANKIND entry into next‑generation CAR‑T cancer therapies and expands its footprint in Europe and the United States.
- The board meeting took place on 15 Oct 2026, from 18:00 IST to 19:00 IST; no financial results or guidance were disclosed.
Mankind Pharma's 70% acquisition of Armed Cell Therapeutics B. V. for EUR 48M (~₹450 Cr) cash in instalments marks a key strategic entry into next-generation CAR-T cancer therapies.
Sign in for impact outlook, horizons, comparables, and full intelligence analysis.
Forecast from comparable, historic events. Not investment advice.
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka